Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-Specific TCR-T Cells With Anti-PD1 Auto-secreted Element in EBV-Positive Head and Neck Carcinoma
NCT04139057Phase 2Completed
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2019
- Primary completion
- Jan 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EBV-specific TCR-T cell with cytokine auto-secreting element in head and neck squamous cell carcinoma (HNSCC), sponsored by Xinqiao Hospital. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Mar 2019; status: completed.
02
Drugs
EBV-specific TCR-T cell with cytokine auto-secreting element
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04139057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139057.